DOSE DENSE HIGH DOSE METHYLPREDNISOLONE (HDMP) AND RITUXIMAB (RTX) ARE EFFECTIVE IN RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION (17P DEL) / TP53 MUTATION

被引：0
|
作者：
Pileckyte, R. [1 ]
Valceckiene, V. [1 ]
Zvirblis, T. [1 ]
Griskevicius, L. [1 ]
机构：
[1] Vilnius Univ Hosp Santariskiu Clin, Vilnius, Lithuania
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1294
引用
收藏
页码：525 / 526
页数：2
相关论文
共 50 条
  • [31] Mutational Status of the TP53 Gene as a Predictor of Response and Survival in CLL Patients with and without 17p Deletion
    Gonzalez, David
    Martinez, Pilar
    Wade, Rachel
    Hockley, Sarah Lorna
    Brito-Babapulle, Vasantha
    Oscier, David Graham
    Matutes, Estelia
    Dearden, Claire E.
    Richards, Sue
    Catovsky, Daniel
    Morgan, Gareth J.
    BLOOD, 2008, 112 (11) : 291 - 291
  • [32] Copy Number Aberrations are Significantly Increased in High-Risk, Untreated CLL Patients with Chromosome 17p Deletion and TP53 Mutation
    Stone, A.
    Carter, W.
    Frederick, L.
    Zent, C. S.
    Viswanatha, D. S.
    Schichman, S. A.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2013, 15 (06): : 870 - 870
  • [33] Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival
    Chin, M.
    Sive, J. I.
    Allen, C.
    Roddie, C.
    Chavda, S. J.
    Smith, D.
    Blombery, P.
    Jones, K.
    Ryland, G. L.
    Popat, R.
    Rismani, A.
    D'Sa, S.
    Rabin, N.
    Gale, R. E.
    Yong, K. L.
    BLOOD CANCER JOURNAL, 2017, 7 : e610 - e610
  • [34] The gene expression signature associated with TP53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under-expression of TP53 and other genes on chromosome 17p
    Lin, Ke
    Lane, Brian
    Carter, Anthony
    Johnson, Gillian G.
    Onwuazor, Obiageli
    Oates, Melanie
    Zenz, Thorsten
    Stilgenbauer, Stephan
    Atherton, Mark
    Douglas, Angela
    Ebrahimi, Bahram
    Sherrington, Paul D.
    Pettitt, Andrew R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 160 (01) : 53 - 62
  • [35] Relative efficacy of systemic treatments for patients with relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis according to 17p deletion/TP53 mutations
    Kim, Jinchul
    Cho, Jinhyun
    Lim, Joo Han
    Lee, Moon Hee
    BLOOD RESEARCH, 2025, 60 (01)
  • [36] What Do We Do with Chronic Lymphocytic Leukemia with 17p Deletion?
    Sellner, L.
    Denzinger, S.
    Dietrich, S.
    Glimm, H.
    Merkel, O.
    Dreger, P.
    Zenz, T.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2013, 8 (01) : 81 - 90
  • [37] 17p Deletion in Chronic Lymphocytic Leukemia Risk Stratification and Therapeutic Approach
    Schnaiter, Andrea
    Stilgenbauer, Stephan
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2013, 27 (02) : 289 - +
  • [38] What Do We Do with Chronic Lymphocytic Leukemia with 17p Deletion?
    L. Sellner
    S. Denzinger
    S. Dietrich
    H. Glimm
    O. Merkel
    P. Dreger
    T. Zenz
    Current Hematologic Malignancy Reports, 2013, 8 : 81 - 90
  • [39] Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival
    M Chin
    J I Sive
    C Allen
    C Roddie
    S J Chavda
    D Smith
    P Blombery
    K Jones
    G L Ryland
    R Popat
    A Rismani
    S D'Sa
    N Rabin
    R E Gale
    K L Yong
    Blood Cancer Journal, 2017, 7 : e610 - e610
  • [40] Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with del(17p)
    de Lacerda, Marcelo Pitombeira
    Guedes, Nayara Ribeiro
    Yamakawa, Patricia Eiko
    Pereira, Andre Domingues
    Medeiros da Fonseca, Ana Rita Brito
    Lopes Ferrari de Chauffaille, Maria Lourdes
    Goncalves, Matheus Vescovi
    Yamamoto, Mihoko
    Rodrigues, Celso Arrais
    ANNALS OF HEMATOLOGY, 2017, 96 (09) : 1577 - 1578
12345